7 recruiting, 4 completed, 1 not yet recruiting. 4 Phase 2, 3 Not applicable, 3 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Completed 1 |
| Not applicable | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow T1D: new trials by email Literature Review of T1D trials Research Report on T1D
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-Exercise Whey and Pea Protein in Adolescents With Type 1 Diabetes low whey protein, moderate whey protein, low Pea protein - T1D, T1DM | Not applicable | Not yet recruiting | University of Jordan | 30 | 2026-10-01 | 2026-09-23 |
| Evaluation of the Accuracy and Safety of a Continuous Glucose Monitoring System GS3 CGM - type1diabetes, CGM | Not applicable | Recruiting | SiBionics, Co, Ltd | 36 | 2026-06-01 | 2026-08-04 |
| A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar Tirzepatide, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM), Carbohydrate Counting - Type 1 Diabetes, Type 1 Diabetes Mellitus | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 105 | 2026-05-19 | 2026-05-27 |
| Simultaneous Measurement and Responsive Treatment - Part 2 DPP System (Insulin Pump and Continuous Glucose Monitoring Platform) - Type 1 Diabetes Mellitus, T1D | Early Phase 1 | Recruiting | ClinSurge Research | 40 | 2026-05-19 | 2026-06-23 |
| Evaluation of a Biopsychosocial System Use of Biopsychosocial Sensing System - T1D, Type 1 Diabetes (T1D) | Completed | Adhera Health, Inc. | 30 | 2025-11-24 | 2026-05-22 | |
| DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions Adhera Caring Digital Program-Obesity (ACDP-O) - Type 1 Diabetes, T1D | Not applicable | Recruiting | Adhera Health, Inc. | 280 | 2025-10-30 | 2026-06-23 |
| A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus OPF-310 - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Recruiting | Otsuka Pharmaceutical Factory, Inc. | 13 | 2025-06-10 | 2026-08-21 |
| Validation of a Computerised Adaptive Test for Measuring Caregiver Well-being CAT well-being test - T1D | Completed | Adhera Health, Inc. | 108 | 2025-05-26 | 2025-12-03 | |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) CNP-103, Placebo - Type 1 Diabetes Mellitus, T1D | Phase 1 / Phase 2 | Recruiting | COUR Pharmaceutical Development Company, Inc. | 72 | 2025-05-12 | 2026-09-11 |
| Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors SGLT-2 inhibitor - Diabetes, Type1diabetes | Phase 1 | Completed | McGill University | 24 | 2024-12-05 | 2026-09-25 |
| Type 1 Diabetes Extension Study Type 1 Diabetes Mellitus, T1DM | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 111 | 2016-06-08 | 2026-09-18 | |
| Tocilizumab (TCZ) in New-onset Type 1 Diabetes Tocilizumab (TCZ), Placebo, Standard of Care - Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 136 | 2015-03-12 | 2021-09-08 |
Diabetes Mellitus, Type 1 (9) · Diabetes Mellitus (3) · Overweight (2) · Asthma (1) · Autoimmune Diseases (1) · Caregiver Burden (1) · Disease (1) · Glucose Intolerance (1) · Glucose Metabolism Disorders (1) · Hypoglycemia (1) · Immune System Diseases (1) · Insulin Resistance (1) · Metabolic Diseases (1) · Motor Activity (1) · Obesity (1)
Endocrine System Diseases (10) · Nutritional and Metabolic Diseases (10) · Glucose Metabolism Disorders (9) · Metabolic Diseases (9) · Autoimmune Diseases (8) · Immune System Diseases (8) · Diabetes Mellitus (7) · Behavior (2) · Body Weight (2) · Nutrition Disorders (2) · Overnutrition (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Behavioral Symptoms (1) · Bronchial Diseases (1)
Sodium-Glucose Transporter 2 Inhibitors (1) · Standard of Care (1) · Therapeutics (1) · Tirzepatide (1) · empagliflozin (1) · tocilizumab (1)
Adhera Health, Inc. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · COUR Pharmaceutical Development Company, Inc. (1) · ClinSurge Research (1) · McGill University (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Otsuka Pharmaceutical Factory, Inc. (1) · SiBionics, Co, Ltd (1) · University of Jordan (1)
United States (4) · Canada (3) · Spain (3) · Australia (1) · China (1) · Switzerland (1)
Ahmad Haidar, PhD (1) · Carla Greenbaum (1) · Jane Buckner, M.D. (1) · Linda A. DiMeglio, MD, MPH,MA (1) · Melissa-Rosina Pasqua, MD, PhD (1) · Michael Tsoukas, M.D. (1) · Paul Peloso, MD (1)